NEW YORK ─ Immucor on Friday announced that it has obtained US Food and Drug Administration clearance for its Luminex single antigen product Lifecodes LSA Class I and Class II Assays in conjunction with its Match It! Antibody Software.
The Norcross, Georgia-based firm said that its Lifecodes LSA Luminex single-antigen assays demonstrate a low false-positive rate, which increases a clinical laboratory's ability to find acceptable donors for transplants.
The regulatory "milestone highlights Immucor's ongoing investment in our transplant antibody portfolio," Christie Otis, the firm's chief marketing officer, said in a statement.
Immucor plans to expand commercialization of its Lifecodes LSA assays to new markets, she added.